Intraperitoneal infusion of recombinant interleukin-2 in malignant ascites in patients with gastrointestinal and ovarian cancer.
In a phase-I-study recombinant interleukin-2 (rIL-2) in a dose from 0.01 to 0.3 mg/m2/day for 7 to 14 days was infused intraperitoneally. Side effects were fever and fluid retention. 2 patients showed a bacterial peritonitis after paracentesis. The investigations showed that the intraperitoneal (i.p.) administration of interleukin-2 activates the whole lymphokine cascade.
Bertoglio
S
S
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Melioli
G
G
Baldini
E
E
Catturich
A
A
Sertoli
M R
MR
Civalleri
D
D
Percivale
P
P
Meier
W
W
Galazka
A
A
Badellino
F
F
D002408:Catheters, Indwelling; D004341:Drug Evaluation; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D006801:Humans; D007263:Infusions, Parenteral / Q000295:instrumentation; D007376:Interleukin-2 / Q000008:administration & dosage*; D010051:Ovarian Neoplasms / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000556:secondary* / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage
D007376:Interleukin-2; D011994:Recombinant Proteins